Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Julius, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Julius, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Bringing VALUE to LIFE

S. Julius*

Division of Hypertension and Hyperlipidemia, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, U.S.A.

* S. Julius, Division of Hypertension and Hyperlipidemia, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109-0356, U.S.A.

Abstract

The results of the LIFE (Losartan Intervention for Endpoint Reduction) trial were the first demonstration that there are differences in outcomes between antihypertensive medications, beyond the reduction in blood pressure. For the first time, a ‘new’ antihypertensive medication, an angiotensin-receptor blocker (ARB) was shown to be superior over an ‘old’ drug, a beta blocker. However, there are questions remaining after LIFE, such as: was the reduction in stroke specific to ARBs? Why were there no greater reductions in cardiovascular mortality? What is the role of monotherapy versus a combination of ARB and a diuretic? Answers to several of these and other questions are expected from the VALUE (Valsartan Antihypertensive Long-term Use Evaluation) trial.

Key Words: Angiotensin receptor blocker • antihypertensive drugs • cardiovascular risk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.